Antimicrobial Resistance and Sensitivity among Isolates of Esherichia coli from Urine Samples in Denizli, Turkey

Abstract

Objective: The research was carried out with isolate and determines the antimicrobial sensitivity in E. coli from urinary tract infections in special hospital in Denizli and recorded at specimens. Methods: Urine samples (n=21) were collected from patients with signs and symptoms of Urinary tract infections. Bacteria were isolated and identified by conventional biochemical profile. Antibiotic resistance pattern of E. coli against different antibiotic was determined by Kirby-Baur method. Results: The results revealed that sensitivity rate of antimicrobial agents were in the range of meropenem (100%), norfloxacin and ciprofloxacin (86%), cefotaxime (80%), aztreonam (76%). None of the samples showed no resistance to amikacin, ceftazidime, aztreonam, amoxicillin/clavulanic acid, and meropenem. Out of 21 isolates, 3(14%) isolates showed Multiple Antibiotic Resistance ten to thirteen antibiotics. Conclusion: It is concluded that most of the urinary tract infections in human are caused by E.coli exhibited highest resistance to meropenem (100%), followed by norfloxacin and ciprofloxacin (86%).We aimed in these research to determine the status of antibiotic resistance, underlying conditions, and isolation of E.coli isolates with from a special hospital in Denizli, Turkey.

Assessment of antimicrobial resistance patterns in Escherichia coli isolated from clinical samples in Madinah, Saudi Arabia

“…The antimicrobial cephalothin showed a low resistance of 0.6% only. The results are 17.3 consistent and in compliance with previous studies (Inan and Gurler, 2004;Kirac et al, 2016). Attention should be given while prescribing cotrimoxazole, Augmentin, and ampicillin to avoid increasing resistance patterns by E. coli.…”

“…Imipenem has been highly effective against Gram-negative bacteria as shown by several other studies (Mohammed et al, 2016;Bahashwan and Shafey, 2013;Dash et al, 2014;Alam et al, 2017). Aztreonam and ciprofloxacin have been recommended as better antimicrobials against E. coli (Kirac et al, 2016).…”

“…It is the leading cause of urinary tract infections (UTIs), blood stream infections, wounds infections, otitis media and other complications in humans (Prestinaci et al, 2015). More than 80% of UTIs occur in outpatients and E. coli accounts for more than 50% of the infections in these patients (Kirac et al, 2016). A rise in antimicrobial resistance has been reported in E. coli worldwide which is causing complications and treatment issues (Zowawi, 2016).…”

Evaluating the antimicrobial resistance patterns and MDR frequency in Escherichia coli strains isolated from clinical specimens taken from patients in Iran: 2017–2019

“…These results indicate that unlike amikacin, ampicillin is not suitable for the treatment of E. coli infections in Iran. Moreover, resistance to carbapenems among isolates collected from Bu-Ali Sina hospital in this study was similar to other studies in Iran and neighboring countries (13,19,21,22,25), while the reported carbapenem resistance rates in non-neighboring countries such as Malaysia and Nigeria were 29.2% and 19.7%, respectively (26,27). This discrepancies may be due to the differences in the type of sample, as Bu-Ali Sina hospital is a specialized pediatric hospital.…”

“…An Iranian study performed in 2019 showed that 2.2% of the clinical isolates of E. coli were resistant to this antibiotic (17). However, other studies conducted in Iran 18, Saudi Arabia (12) and Turkey (19), detected no amikacin resistant isolates of E. coli. These results indicate the good e cacy of amikacin as one of the effective antibiotics against infections caused by E. coli.…”